Intranasal immunization with multivalent group A streptococcal vaccines protects mice against intranasal challenge infections.
about
Correlates of Protection for M Protein-Based Vaccines against Group A StreptococcusInnate immune function of the neisserial porins and the relationship to vaccine adjuvant activityVaccination against the M protein of Streptococcus pyogenes prevents death after influenza virus: S. pyogenes super-infection.Bactericidal activity of M protein conserved region antibodies against group A streptococcal isolates from the Northern Thai population.Local Th17/IgA immunity correlate with protection against intranasal infection with Streptococcus pyogenes.Protective efficacy of group A streptococcal vaccines containing type-specific and conserved M protein epitopes.M protein gene (emm type) analysis of group A beta-hemolytic streptococci from Ethiopia reveals unique patterns.A novel live vector group A streptococcal emm type 9 vaccine delivered intranasally protects mice against challenge infection with emm type 9 group A streptococci.Intranasal DNA Vaccine for Protection against Respiratory Infectious Diseases: The Delivery Perspectives.Disease manifestations and pathogenic mechanisms of Group A Streptococcus.Mucosal adjuvants and delivery systems for protein-, DNA- and RNA-based vaccines.The role of adjuvants in the development of mucosal vaccines.Prospects for a group A streptococcal vaccine: rationale, feasibility, and obstacles--report of a National Institute of Allergy and Infectious Diseases workshop.Therapies for necrotising fasciitis.Vaccine based on a ubiquitous cysteinyl protease and streptococcal pyrogenic exotoxin A protects against Streptococcus pyogenes sepsis and toxic shock.Mucosal vaccination against bacterial respiratory infections.Moving forward: a mucosal vaccine against group A streptococcus.Mucosal Vaccine Development Based on Liposome Technology.Recent progress towards development of a Shigella vaccine.Nasal-nanotechnology: revolution for efficient therapeutics delivery.Prospective Longitudinal Analysis of Immune Responses in Pediatric Subjects After Pharyngeal Acquisition of Group A Streptococci.Immunogenicity of a divalent group A streptococcal vaccine.Binding host proteins to the M protein contributes to the mortality associated with influenza-Streptococcus pyogenes superinfections.The Streptococcus pyogenes fibronectin/tenascin-binding protein PrtF.2 contributes to virulence in an influenza superinfection
P2860
Q27009175-B905AEAC-D27A-4B01-94E5-B2EA0DAA91F4Q30156878-A7D5D48E-957D-41AF-B7C5-A247D20EFA0EQ30586381-01578712-17E3-446D-9810-70C6400C32B4Q33253260-92DD4616-D063-4756-9F2A-DF025D088276Q33570612-3FE1D223-EF32-4DB4-8ABC-736B9A9F8746Q34005434-FC81026B-4001-48CF-B638-98666DF28B3EQ34042270-84E994FA-C939-468B-B6AE-AA261A4B9D83Q34260712-25EFE7A8-66E4-4BB1-8607-E72055651920Q34309830-7CC5A565-9659-4C48-B096-BB206FA0823DQ34413457-6022FB15-64DD-45C5-8EF2-C5B6CEC87E04Q35953762-90F67D84-243E-4917-8413-6F9762263A8BQ36194084-B49AB815-6970-4F2E-8927-EA4A166FE72EQ36257688-007A220C-7C3C-44D5-8B28-146A58B9103BQ36377217-AE5BCC99-17FC-4A27-A279-CB67C78EB3CAQ36977951-9A3DFF98-4A38-4EC8-8DB3-510E80527E1AQ37290114-74FB9EB5-C188-41A1-882D-746816A4216FQ37503248-BF582275-B395-4CE4-ABA6-30609B2B451FQ37581129-747E39C5-C939-49E4-9920-4E0130EC00FBQ38068954-83B8DA01-4264-4E7D-A5B6-EF7DAE62C91DQ38217878-D9705F2D-F57F-4DBE-9B0D-EE845FE73AAEQ40068749-2DC6CB8A-581A-4EA1-A962-1E6A75984785Q40278264-9C24518A-18DB-45F1-8E0C-8359183098D4Q41931158-C00044D4-1D49-47F5-9E30-D1AFF9D3C890Q58783155-A7181BAF-59B9-4A31-B489-FE64F9937994
P2860
Intranasal immunization with multivalent group A streptococcal vaccines protects mice against intranasal challenge infections.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on May 2004
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Intranasal immunization with m ...... tranasal challenge infections.
@en
Intranasal immunization with m ...... tranasal challenge infections.
@nl
type
label
Intranasal immunization with m ...... tranasal challenge infections.
@en
Intranasal immunization with m ...... tranasal challenge infections.
@nl
prefLabel
Intranasal immunization with m ...... tranasal challenge infections.
@en
Intranasal immunization with m ...... tranasal challenge infections.
@nl
P2093
P2860
P1476
Intranasal immunization with m ...... ntranasal challenge infections
@en
P2093
David S Burt
George H Lowell
Mark A Reddish
Mary A Hall
Michael A Walls
Steven D Stroop
P2860
P304
P356
10.1128/IAI.72.5.2507-2512.2004
P407
P50
P577
2004-05-01T00:00:00Z